RARE DISEASERESEARCH ATLAS
Open navigation menu

ORPHA:52417

MALT lymphoma

high confidenceDisorder

Also known as: Extranodal marginal zone B-cell lymphoma · MALToma · Mucosa-associated lymphatic tissue lymphoma · Mucosa-associated lymphoid tissue lymphoma

Publications

58,616

99th percentile

Trials

172

Interventional, condition-specific

Researchers

1,040

Distinct authors in sample

Gene link

—

Readiness

5/6

Stages with a signal

Clinical definition (Orphanet)

MALT (mucosa-associated lymphoid tissue) lymphoma is a rare form of malignant non-Hodgkin lymphoma that affects B cells and grows at the expense of lymphoid tissue associated with mucous membranes, but also occurs, more rarely, in lymph nodes.

How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.

Orphanet entry

Cross-references

Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.

Additional Mondo synonyms (9)

Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue · Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT-lymphoma) · Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue · Immunocytoma · MALT-lymphoma · lymphoma of mucosa-associated lymphoid tissue · lymphoma, MALT, somatic · mucosa-associated lymphatic tissue lymphoma · mucosa-associated lymphoid tissue lymphoma

Research stages

Trial readiness signals

Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”

5/6 stages with a signal

An interventional trial matched this condition name on ClinicalTrials.gov — see trials below.

  1. Gene identifiedNot found

    No GenCC disease–gene assertion in this build

  2. LiteraturePresent

    58,616 matched papers (28,410 in last 10 years) Source

  3. Phenotype characterisedPresent

    18 HPO annotations (e.g. Gastric lymphoma; Abnormal nasolacrimal system morphology; Abnormality of the thyroid gland) Source

  4. Animal modelPresent

    1 genotype model (Mus musculus) Source

  5. Orphan designationPresent

    12 FDA designations (7 FDA orphan-indication approvals) — e.g. zanubrutinib Source

  6. Interventional trialPresent

    172 matched on ClinicalTrials.gov (15 recruiting in sample)

Biology

Genes and phenotypes

Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.

Do we know what causes it?

Not yet — the cause hasn't been pinned down in GenCC.

No strong gene–disease assertion joined for this Orphanet entity.

Phenotypes (Monarch / HPO)

18

Associated phenotypes · MONDO:0007650

  • Gastric lymphoma
  • Abnormal nasolacrimal system morphology
  • Abnormality of the thyroid gland
  • Abdominal pain
  • Pulmonary infiltrates

Showing 5 of 18 — open Monarch for the full list.

Animal models (Monarch / Alliance)

1

Model associations linked to this Mondo ID

Monarch fetch 2026-07-29

Therapies

Designations, candidates, and chemicals

FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.

Orphan designation (FDA · EMA)

12

Designations · 7 with FDA orphan-indication approval

  • FDA zanubrutinibNodal marginal zone lymphoma · 2020-08-24 · Not FDA Approved for Orphan Indication
  • FDA axicabtagene ciloleucelNodal marginal zone lymphoma · 2020-03-24 · Not FDA Approved for Orphan Indication
  • FDA parsaclisibNodal marginal zone lymphoma · 2019-10-07 · Not FDA Approved for Orphan Indication
  • FDA copanlisibNodal marginal zone lymphoma · 2017-02-07 · Not FDA Approved for Orphan Indication
  • FDA idelalisibNodal marginal zone lymphoma · 2013-10-15 · Not FDA Approved for Orphan Indication
  • FDA ublituximabNodal marginal zone lymphoma · 2013-09-05 · Not FDA Approved for Orphan Indication
  • FDA ublituximabmarginal zone lymphoma Marginal zone lymphoma · 2013-09-05 · Not FDA Approved for Orphan Indication
  • FDA umbralisib (Ukoniq)Nodal marginal zone lymphoma · 2019-04-11

Sources: FDA OOPD · EMA orphan designations

Open Targets candidates

26

Drugs / clinical candidates · MONDO_0007650

CTD chemicals (MyDisease.info)

No CTD chemical associations returned for this Mondo ID.

Literature

Is anyone studying this?

58,616

58,616 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.

58,616 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).

28,410 in the last 10 years · high confidence · 99th percentile (publications denominator)

Phrase hits: 19,155 · MeSH hits: 0

Open Europe PMC search

Who's working on it?

1,040

Distinct author names in 200 sampled papers — named people below.

Who's working on it?

People publishing on this condition (sampled Europe PMC records). Affiliation is the most recent found in that sample.

  1. 01
    Wang X8 papers · 2026

    Department of Pathology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.

    Papers in Europe PMC
  2. 02
    Zhang Y8 papers · 2026

    Department of Hematology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing 100730, China.

    Papers in Europe PMC
  3. 03
    Chen J6 papers · 2026

    Department of Pathology, The Third Affiliated Hospital, Sun Yat-sen University, No. 600 Tianhe Road, Guangzhou, 510630, China. chjning@mail.sysu.edu.cn.

    Papers in Europe PMC
  4. 04
    Chen Y6 papers · 2026

    Department of Stomatology, The First Affiliated Hospital of Bengbu Medical College Bengbu, Anhui, P. R. China.

    Papers in Europe PMC
  5. 05
    He Y6 papers · 2026

    Department of Radiation Oncology, The First Affiliated Hospital of Zhejiang University School of Medicine, Hangzhou, Zhejiang 310003, People's Republic of China; Zhejiang University Cancer Center, Hangzhou, Zhejiang 310003, People's Republic of China.

    Papers in Europe PMC
  6. 06
    Li J6 papers · 2026

    Department of Hematology, Lymphoma Center, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

    Papers in Europe PMC
  7. 07
    Raderer M6 papers · 2026

    Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria.

    Papers in Europe PMC
  8. 08
    Wang J6 papers · 2026

    Department of Stomatology, The First Affiliated Hospital of Bengbu Medical College Bengbu, Anhui, P. R. China.

    Papers in Europe PMC
  9. 09
    Kiesewetter B5 papers · 2026

    Department of Medicine I, Division of Oncology, Medical University of Vienna, Vienna, Austria.

    Papers in Europe PMC
  10. 10
    Liu S5 papers · 2026

    Department of Radiation Oncology, Jiangsu Province Hospital, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.

    Papers in Europe PMC

Clinical research

Is a treatment being tested?

172

interventional trials for this specific condition

172 interventional trials matched this specific condition name; 15 currently recruiting in our sample.

Data as of 11 September 2026

172 interventional trials — more than 77.2% of diseases in the trials denominator have none at all (5501 of 7126; this disease is at the 99.1th percentile).

high confidence · 99.1th percentile (trials denominator)

Recruiting interventional trials

From the matched ClinicalTrials.gov set

172 interventional trials matched after quoted-phrase search and title/condition post-filter.

Observational and natural-history studies

8 observational studies match this condition. These do not test a treatment and are not counted in the interventional-trial headline, but they are genuine research: natural-history work often defines the endpoints needed for a future rare-disease trial, and families may be able to enroll.

Recruiting or not-yet-recruiting

Open the complete matched search on ClinicalTrials.gov

Other registries (secondary)

Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.

raw 11 · after dedupe 11 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 11 · dropped 0 · fetched 2026-07-29

Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri

No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).

Uncertain / not reviewed (11)

Where to find support

Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.

Orphanet entry for MALT lymphoma — check Associations / patient organisations on that page.

India — NPRD

Last verified 2026-07-26

This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.

Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.

How we counted this

Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.

("MALT lymphoma" OR "Extranodal marginal zone B-cell lymphoma" OR "MALToma" OR "Mucosa-associated lymphatic tissue lymphoma" OR "Mucosa-associated lymphoid tissue lymphoma" OR "Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue" OR "Extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue" OR "Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT-lymphoma)" OR "Extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT-lymphoma)" OR "Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue" OR "Extranodal marginal zone lymphoma of the mucosa-associated lymphoid tissue" OR "Immunocytoma" OR "MALT-lymphoma" OR "lymphoma of mucosa-associated lymphoid tissue" OR "lymphoma of the mucosa-associated lymphoid tissue" OR "lymphoma, MALT, somatic") OR ("MALT" OR "MALT syndrome" OR "MALT-related")

Run this search on Europe PMC

ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):

"MALT lymphoma" OR "Extranodal marginal zone B-cell lymphoma" OR "MALToma" OR "Mucosa-associated lymphatic tissue lymphoma" OR "Mucosa-associated lymphoid tissue lymphoma" OR "Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue" OR "Extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue" OR "Extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue (MALT-lymphoma)" OR "Extranodal marginal zone B-cell lymphoma of the mucosa-associated lymphoid tissue (MALT-lymphoma)" OR "Extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue" OR "Extranodal marginal zone lymphoma of the mucosa-associated lymphoid tissue" OR "Immunocytoma" OR "MALT-lymphoma" OR "lymphoma of mucosa-associated lymphoid tissue" OR "lymphoma of the mucosa-associated lymphoid tissue" OR "lymphoma, MALT, somatic"

Interventional trials matched via: phrase (mesh = registered under a MeSH descriptor no name phrase would catch; recall-expansion = gene / selected parent terms used only for trials).

Study-type breakdown: 172 interventional · 8 observational · 0 expanded access. Only interventional studies enter the trial headline.

Query health: ok — strategies attempted: phrase; with hits: phrase

Run this search on ClinicalTrials.gov

Confidence reasoning

  • Preferred label is multi-word and distinctive
  • No synonyms dropped by stoplist
  • No label/synonym collisions with other diseases in this corpus

Ingested 2026-07-27T00:49:04.888Z